Anke Biotech announced that the clinical trial application for AK2405, an innovative drug developed independently by the company, was accepted by the State Drug Administration. This product is an antibody-conjugated drug targeting HER2. It is registered and classified as a therapeutic biological product class 1. The proposed indication is advanced malignant solid tumors. Preclinical studies have shown that it has high specificity and high anti-tumor activity. This acceptance is only a phased result of the development of a new drug, and there is still uncertainty about whether it will be approved for clinical trials and marketing.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.